High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer - Wikidata - awgldk - TriplyDB

High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer

High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer

http://www.wikidata.org/entity/Q34048024

about

Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics MicroRNA-296 is enriched in cancer cells and downregulates p21WAF1 mRNA expression via interaction with its 3' untranslated region WSB1: from homeostasis to hypoxia Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential An integrative genomic and transcriptomic analysis reveals potential targets associated with cell proliferation in uterine leiomyomas Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer Discovering subgroups of patients from DNA copy number data using NMF on compacted matrices.Language-Agnostic Reproducible Data Analysis Using Literate Programming.Integrated analysis of genome-wide copy number alterations and gene expression in microsatellite stable, CpG island methylator phenotype-negative colon cancer.A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications.High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer.Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns.Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer Systems consequences of amplicon formation in human breast cancer MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1.Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.New network topology approaches reveal differential correlation patterns in breast cancer.Concurrent gene signatures for han chinese breast cancers Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers.Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes.A refined molecular taxonomy of breast cancer.Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer MIEN1, a novel interactor of Annexin A2, promotes tumor cell migration by enhancing AnxA2 cell surface expression.A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22.Functional characterization of the 19q12 amplicon in grade III breast cancers Palindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumors Challenges in identifying candidate amplification targets in human cancers: chromosome 8q21 as a case study.Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer.Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).An integrated genomics analysis of epigenetic subtypes in human breast tumors links DNA methylation patterns to chromatin states in normal mammary cells.A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers Identification of Copy Number Aberrations in Breast Cancer Subtypes Using Persistence Topology.HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression.Endoplasmic reticulum factor ERLIN2 regulates cytosolic lipid content in cancer cells Receptor protein-tyrosine phosphatase α regulates focal adhesion kinase phosphorylation and ErbB2 oncoprotein-mediated mammary epithelial cell motility.Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer MIEN1 drives breast tumor cell migration by regulating cytoskeletal-focal adhesion dynamics

P2860

Q24595882-836180A6-D450-4646-AD63-2F87EE9662F0 Q24635277-E60EC945-501E-4DCF-BE99-D6F186ABCDB0 Q26740274-472A5EAD-C226-41D1-91BC-10FBC7477996 Q26782613-B6D31DC6-7DA6-4403-B6EE-52FFCF09CF2D Q28487526-296EEE34-8257-4EE7-B7A7-7DC83D4B3E7D Q28741460-88A539AC-8FCE-4C32-9EEA-5927FDA37149 Q30701692-4B92121D-FF26-4883-9B26-F1641CBE4300 Q31135215-5B937206-08D8-40DD-9AD5-65984D3B75F3 Q33604452-E3AE3AA5-A414-434B-8FA8-530920B5FD26 Q33739397-D9C81C37-C58B-448A-893B-1E197B829684 Q33757555-C045A8A6-8675-4C1F-BE8B-8F1EAF8CA237 Q34010867-630FBAA0-12F0-4D63-93B3-FE55186231CB Q34048118-C2EF9002-3321-416E-8DE5-9BB8E56656E6 Q34120668-F212A18D-C230-4939-A5AA-709C6AEB1290 Q34350077-3CE3AEF4-A588-46F9-A92A-5A789DCC31CA Q34582195-32C9AF14-B01C-4CAD-ADC8-FF00AD83151B Q34615545-A9487ED1-053A-4E5F-B3F6-69A1BA12297C Q34941536-058E4E94-EA71-451F-A0FE-F857302C6012 Q35009429-85DB5AFC-CC32-4236-9938-91FC10959B66 Q35029573-20C8BF02-5316-4298-B303-5C245F0C926D Q35558105-205DCDD8-949D-4396-A3DE-F4E443B1E88F Q35838290-94510F92-CFC0-4F5D-B141-E68AEF3966E0 Q35889655-3498E7A8-5C05-4E16-92A0-7A4F076E2E5A Q35953723-82243F7D-9E68-46E0-89B9-C4266F6F8C63 Q36234011-7A4879B1-34F0-4C26-A06D-4BF2ED082F28 Q36245567-461F5926-8E5B-4D22-B783-F4C88A417604 Q36283885-1EE51524-E2BB-43B3-8D79-68671C8F6A46 Q36296457-AF5F4AA4-F49C-4D1B-BB96-02E90B350023 Q36438357-434163D9-223D-43DC-9F12-BAF4BEE38CF5 Q36499925-EE8F0236-DBC5-4242-A340-B1038CE59A29 Q36551617-5A5D92D7-F4DB-47D0-A40A-EF625E709FF3 Q36618624-293B6B80-DD14-4196-A60A-F4B757135276 Q36628822-A48F1AA7-137B-4D0E-AE8A-BE21A173F2B6 Q37099507-849A2D06-47B4-47C9-8D12-19FD815096FF Q37200784-AF00829F-0DFB-4A7D-BA05-D00B9D16D233 Q37216946-E15CA83F-477B-4ACF-96ED-B1808D24D082 Q37250797-78422D6D-3383-46EE-A39A-85A2E220A4B1 Q37415599-23A3B419-2AB7-48BD-B3B5-7440A6B20035 Q37636623-8E52005F-8A9F-4585-A11B-C65C694BEA6A Q37688163-32BE9858-A6CD-458D-881B-4720D54472D4

P2860

High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer

http://www.wikidata.org/entity/Q34048024

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

High-resolution genomic and ex ...... n HER2-amplified breast cancer

@ast

High-resolution genomic and ex ...... n HER2-amplified breast cancer

@en

High-resolution genomic and ex ...... n HER2-amplified breast cancer

@nl

type

label

High-resolution genomic and ex ...... n HER2-amplified breast cancer

@ast

High-resolution genomic and ex ...... n HER2-amplified breast cancer

@en

High-resolution genomic and ex ...... n HER2-amplified breast cancer

@nl

prefLabel

High-resolution genomic and ex ...... n HER2-amplified breast cancer

@ast

High-resolution genomic and ex ...... n HER2-amplified breast cancer

@en

High-resolution genomic and ex ...... n HER2-amplified breast cancer

@nl

P1433

Q34048024-23B7D2D0-B87C-4BE0-A1A3-6B3961C83D2E

P1476

Q34048024-A7AF9EBD-1DCC-40FB-9C74-F7C2385D244F

P2093

Q34048024-1198D79C-6B7E-40B2-A917-D9115DE3EBF5

Q34048024-23E670CA-FFC6-48BE-BB37-FB38513772E7

Q34048024-3C0371A1-9E35-408D-851F-47CEC7535609

Q34048024-6D9A6AF7-E2DA-4549-8086-07567259CC38

Q34048024-6F078063-3C1F-4BB8-AE95-071308F33762

Q34048024-87F98197-35E6-4205-95D3-9BED7F0A538F

Q34048024-8EEEE623-8E32-4B3D-914C-5173BC6C11BC

Q34048024-9FE51B30-32B1-403C-BD88-7129BA2D09BE

Q34048024-CC22A4B3-78A0-4087-B30E-D07BFAAF8D00

Q34048024-CDB0087C-0FBA-41F0-9DBA-2B5C768F03E4

P2860

Q34048024-051A104A-16A2-4BA9-A9DC-73C9DCC3E24F

Q34048024-06179C60-7102-41CB-9883-87415E16159E

Q34048024-0A3746FE-6946-49DF-A00F-B0747B3BDFA7

Q34048024-0DFF1BFF-2D92-4187-AA89-8AF9A5CFE828

Q34048024-0E1F0B2F-424D-414F-8A61-6264D3AE4EED

Q34048024-1071FDFB-8FB3-4523-A397-F4B6792E0FBE

Q34048024-194259BC-A4AE-4BE7-B429-EBD466296669

Q34048024-1C2F8B0B-D469-4C28-B408-8F717A5433FC

Q34048024-1FCB6D7D-50A7-4EDF-88C0-0B5C47C5A6A8

Q34048024-20CC1F85-BC67-49B4-961D-4941B987FB1B

P2888

Q34048024-ED8BBCB3-F4FB-46FE-9BEE-A98BF6C14E44

P304

Q34048024-133BCB56-10FD-44D8-9408-478D7E77DD51

P31

Q34048024-2A9079AA-EF28-4EEE-85C0-7567A2A5A351

P356

Q34048024-111F5817-F40C-4E93-89C2-CA221D8D6575

P433

Q34048024-945AF064-C0F1-46F2-8014-B0C95DE9A14D

P478

Q34048024-C1F3A4A9-0A26-44B8-BF76-5EFFADB15FEF

P50

Q34048024-7695C22C-2BA9-42D4-B6CA-337727DF81DA

Q34048024-FC23941A-4933-4BD7-8ABA-11B61A12E2BE

Q34048024-FF901768-9727-46C5-9A25-F2FE648E4A81

P577

Q34048024-215110FC-D4C3-4C71-AA87-CCAA4AA68A47

P5875

Q34048024-B48BAA9E-3818-468A-9F59-25BC8C0291F2

P6179

Q34048024-5EA830DA-42ED-4AB6-BCC4-6839B9F9FD7F

P698

Q34048024-B1D9395F-9995-45EF-892C-F58E7C0B721A

P932

Q34048024-B9E0C69C-491D-4248-8043-BBA3E56F8108

P356

P1433

Breast Cancer Research

P1476

High-resolution genomic and ex ...... n HER2-amplified breast cancer

@en

P2093

Ake Borg

http://www.w3.org/2001/XMLSchema#string

Bjarni A Agnarsson

http://www.w3.org/2001/XMLSchema#string

Dorthe Grabau

http://www.w3.org/2001/XMLSchema#string

Göran Jönsson

http://www.w3.org/2001/XMLSchema#string

Haukur Gunnarsson

http://www.w3.org/2001/XMLSchema#string

Johan Staaf

http://www.w3.org/2001/XMLSchema#string

Niklas Loman

http://www.w3.org/2001/XMLSchema#string

Oskar Th Johannsson

http://www.w3.org/2001/XMLSchema#string

Per-Olof Malmström

http://www.w3.org/2001/XMLSchema#string

Rosa B Barkardottir

http://www.w3.org/2001/XMLSchema#string

P2860

The CD44+/CD24- phenotype is enriched in basal-like breast tumors

Structural determinants of the interaction between the erbB2 receptor and the Src homology 2 domain of Grb7

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Molecular portraits of human breast tumours

Repeated observation of breast tumor subtypes in independent gene expression data sets

Association of focal adhesion kinase with Grb7 and its role in cell migration

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

P2888

P304

R25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR2568

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Johan Vallon-Christersson

Markus Ringnér

Adalgeir Arason

P577

2010-05-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44589365

http://www.w3.org/2001/XMLSchema#string

P6179

1014945794

http://www.w3.org/2001/XMLSchema#string

P698

20459607

http://www.w3.org/2001/XMLSchema#string

P932

2917012

http://www.w3.org/2001/XMLSchema#string